GlassScriptPhysician profile
Colin Lacroix
NPI 1912219593
$93,329.50
in general payments reported to CMS, 2019-2025
63 companies · $925 in 2025
The $925 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,016 · 2020: $18K · 2021: $23K · 2022: $15K · 2023: $18K · 2024: $17K · 2025: $925.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $5,005 · Honoraria: $2,275 · Travel and Lodging: $2,131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,500.00 |
| Food and Beverage | $5,005.19 |
| Honoraria | $2,275.00 |
| Travel and Lodging | $2,130.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $43,927.37 | 2022-2024 | Qelbree, Qelbree |
| Allergan, INC. | $19,878.17 | 2019-2021 | |
| Abbvie INC. | $12,984.21 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $7,086.72 | 2020-2021 | |
| Amgen INC. | $2,052.88 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $707.59 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $596.81 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $547.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $447.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $440.70 | 2019-2025 | Farxiga, Airsupra, Bevespi Aerosphere |
| Axsome Therapeutics, INC. | $364.66 | 2023-2025 | Sunosi, Auvelity |
| Optinose US, INC. | $329.55 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $258.53 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.84 | 2019-2023 | Trintellix |
| Astellas Pharma US INC | $224.72 | 2019-2025 | Veozah, Myrbetriq |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Lacroix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.